Cargando…

Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is a poor outcome subset of breast cancers characterised by the lack of expression of ER α, PR, and HER2 amplification. It is a heterogeneous group of cancers which fail to derive benefit from modern, more targeted treatments such as Tamoxifen and Herceptin. Curr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elkashif, Ahmed, Bingham, Victoria, Haddock, Paula, Humphries, Matthew P., McQuaid, Stephen, Mullan, Paul B., McCarthy, Helen O., Buckley, Niamh E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256765/ https://www.ncbi.nlm.nih.gov/pubmed/32565802 http://dx.doi.org/10.1155/2020/3712825

Ejemplares similares

NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
por: Mullan, Paul B., et al.
Publicado: (2019)

Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer
por: Knowlson, Catherine, et al.
Publicado: (2020)

A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer
por: Buckley, Niamh E., et al.
Publicado: (2016)

Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)
por: Orr, Katy, et al.
Publicado: (2016)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer
por: Wilkinson, Richard D. A., et al.
Publicado: (2019)

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer
por: Humphries, Matthew P., et al.
Publicado: (2018)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer
por: Liao, Gaoming, et al.
Publicado: (2021)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization
por: Humphries, Matthew P., et al.
Publicado: (2020)

PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics
por: Abdullahi Sidi, Fatima, et al.
Publicado: (2020)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015)

Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
por: Zhou, Li-Yan, et al.
Publicado: (2015)

Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer
por: Takeda, Risa, et al.
Publicado: (2015)

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
por: Aomatsu, Naoki, et al.
Publicado: (2014)

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
por: Dai, Kun, et al.
Publicado: (2015)

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
por: Wang, Zhipeng, et al.
Publicado: (2018)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

The role of taxanes in triple-negative breast cancer: literature review [Corrigendum]
Publicado: (2015)

Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology
por: Ntellas, Panagiotis, et al.
Publicado: (2019)

Observations on the transcriptional activity of the glutathione S-transferase pi gene in human haematological malignancies and in the peripheral leucocytes of cancer patients under chemotherapy.
por: McQuaid, S., et al.
Publicado: (1989)

Context-Dependent Diversity-Effects of Seaweed Consumption on Coral Reefs in Kenya
por: Humphries, Austin T., et al.
Publicado: (2015)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment
por: Buckley, Niamh E., et al.
Publicado: (2016)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

Exploring the immune microenvironment in small bowel adenocarcinoma using digital image analysis
por: Sidi, Fatima Abdullahi, et al.
Publicado: (2023)

A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy
por: Cheng, Pu, et al.
Publicado: (2017)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer: A Meta-Analysis of Randomized Trials
por: Zheng, Ruinian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_104b7k237l1ukfhto7mblrutoo